Obstructive Sleep Apnoea as a Cardiometabolic Disorder

Obstructive Sleep Apnoea as a Cardiometabolic Disorder

Obstructive sleep apnoea (OSA) is increasingly recognised as a chronic condition with systemic consequences. Beyond daytime sleepiness and reduced quality of life, untreated OSA contributes to significant cardiovascular and metabolic morbidity.

For primary care practitioners, integrating OSA management into broader chronic disease frameworks is essential.

Pathophysiological Mechanisms Linking OSA to Cardiovascular Disease

OSA is characterised by recurrent upper airway collapse during sleep, leading to intermittent hypoxia and sleep fragmentation. These physiological disturbances trigger:

  • Sympathetic nervous system activation
  • Oxidative stress
  • Systemic inflammation
  • Endothelial dysfunction

These processes contribute to the development and progression of hypertension, coronary artery disease, arrhythmias, and insulin resistance.

The American Heart Association has formally recognised the strong association between sleep apnoea and cardiovascular disease (Somers et al., 2008).

Hypertension and OSA

OSA is highly prevalent among patients with resistant hypertension and non-dipping nocturnal blood pressure patterns.

Meta-analytic data indicate that CPAP therapy produces modest but clinically meaningful reductions in blood pressure, particularly in adherent individuals (Bratton et al., 2015).

Even small reductions in systolic blood pressure can reduce stroke and cardiovascular event risk at the population level.

Atrial Fibrillation and Recurrence

Emerging evidence supports an association between OSA and atrial fibrillation (AF), including increased recurrence rates following cardioversion or ablation in untreated patients.

Recognition and management of OSA in cardiology patients may improve rhythm control outcomes and reduce recurrence risk.

Clinical Monitoring Considerations

For patients with diagnosed OSA, ongoing monitoring should include:

  • Blood pressure trends
  • Glycaemic control
  • Weight and metabolic markers
  • CPAP adherence data
  • Assessment of residual symptoms

OSA management should be incorporated into routine chronic disease review rather than treated as a separate entity.

Collaborative Model of Care

Optimal management requires coordination between:

  • Primary care
  • Sleep physicians
  • Cardiologists
  • CPAP service providers

Equipment optimisation, adherence monitoring, and early troubleshooting are practical components that support long-term treatment efficacy. OSA is a systemic disorder with measurable cardiometabolic consequences. Early identification, structured CPAP management, and multidisciplinary coordination are critical in reducing long-term morbidity.

For clinicians, treating OSA effectively is an integral part of comprehensive cardiovascular risk reduction.

References (APA 7th)
Bratton, D. J., Gaisl, T., Wons, A. M., & Kohler, M. (2015). CPAP vs mandibular advancement devices and blood pressure in patients with OSA: A systematic review and meta-analysis. JAMA, 314(21), 2280–2293. https://doi.org/10.1001/jama.2015.16303
Somers, V. K., White, D. P., Amin, R., et al. (2008). Sleep apnea and cardiovascular disease: An American Heart Association scientific statement. Circulation, 118(10), 1080–1111. https://doi.org/10.1161/CIRCULATIONAHA.107.189420
Shahar, E., Whitney, C. W., Redline, S., et al. (2001). Sleep-disordered breathing and cardiovascular disease: Cross-sectional results of the Sleep Heart Health Study. American Journal of Respiratory and Critical Care Medicine, 163(1), 19–25. https://doi.org/10.1164/ajrccm.163.1.2001008
Back to blog